论文部分内容阅读
尼沙(口替)丁(nizatidine,nz)是一种新型的H_2受体阻滞剂,每晚睡前(hs)口服300mg或每日二次150mg可有效地治疗活动性十二指肠溃疡。本文旨在研究nz缓解胃食管返流疾病(GERD)症状和愈合中、重度食管炎有效和安全的治疗方案。方法:466例(18岁以上)GERD患者随机分为给予nz 150 mg/bid、300 mg/hs和安慰剂三组。患者每隔3周就诊一次以评定耐受性和疗效,共治疗12周。主要的有效指标是内镜证实食管炎完全愈合;次要指标
Nizatidine (nz) is a novel H 2 blocker that is effective in the treatment of active duodenal ulcers (300 mg daily at bedtime (hs) or 150 mg twice daily) . This article aims to study nz to relieve the symptoms of gastroesophageal reflux disease (GERD) and heal the treatment of moderate and severe esophagitis effective and safe treatment. Methods: 466 GERD patients (over 18 years of age) were randomized to receive nz 150 mg / bid, 300 mg / hs and placebo. Patients were referred to the institution every three weeks to assess tolerability and efficacy for a total of 12 weeks. The main effective indicators are endoscopic confirmed esophagitis completely healed; minor indicators